ATE324105T1 - Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken - Google Patents

Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken

Info

Publication number
ATE324105T1
ATE324105T1 AT99937419T AT99937419T ATE324105T1 AT E324105 T1 ATE324105 T1 AT E324105T1 AT 99937419 T AT99937419 T AT 99937419T AT 99937419 T AT99937419 T AT 99937419T AT E324105 T1 ATE324105 T1 AT E324105T1
Authority
AT
Austria
Prior art keywords
cyclooxygenase
neck
head
inhibitor
patient
Prior art date
Application number
AT99937419T
Other languages
English (en)
Inventor
Andrew J Dannenberg
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of ATE324105T1 publication Critical patent/ATE324105T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99937419T 1998-09-08 1999-07-29 Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken ATE324105T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9934398P 1998-09-08 1998-09-08

Publications (1)

Publication Number Publication Date
ATE324105T1 true ATE324105T1 (de) 2006-05-15

Family

ID=22274554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99937419T ATE324105T1 (de) 1998-09-08 1999-07-29 Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken

Country Status (7)

Country Link
US (1) US6486203B1 (de)
EP (1) EP1109553B1 (de)
AT (1) ATE324105T1 (de)
CA (1) CA2339049C (de)
DE (1) DE69931055T2 (de)
ES (1) ES2258337T3 (de)
WO (1) WO2000013685A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US6716883B1 (en) * 1998-12-24 2004-04-06 1333366 Ontario Inc. Composition useful to treat periodontal disease
PE20010540A1 (es) * 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
US7700650B2 (en) 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
HK1054296A1 (zh) * 2000-06-13 2003-11-28 Wyeth 纾缓炎症引致慢性痛楚的植物营养素配方
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
ATE466577T1 (de) 2001-05-03 2010-05-15 Cornell Res Foundation Inc Behandlung von krankheiten, die durch hpv verursacht werden
US6979470B2 (en) * 2001-07-17 2005-12-27 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20030166716A1 (en) 2001-11-06 2003-09-04 Serhan Charles N. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
WO2003051350A1 (en) 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP1545520A4 (de) * 2002-08-22 2008-07-16 Cornell Res Foundation Inc Multifunktionale cox-2-hemmer
CN103211806B (zh) * 2003-05-27 2015-09-09 帝斯曼知识产权资产管理有限公司 新颖的营养药物性组合物及其用途
EP2236131A3 (de) 2003-07-01 2011-03-02 President and Fellows of Harvard College SIRT1 Modulatoren zur Veränderung der Lebensdauer/Stressreaktion von Zellen/Organismen
DE10352368A1 (de) * 2003-11-10 2005-06-09 Beiersdorf Ag Verwendung von Licochalkon A zur Behandlung von Insektenstichen
DE10352369A1 (de) * 2003-11-10 2005-06-09 Beiersdorf Ag Verwendung von Licocalchon A oder eines Licocalchon A enthaltenden Extraktes aus Radix Glycyrrhizae inflatae gegen postinflammatorische Hyperpigmentierung
DE10352367A1 (de) 2003-11-10 2005-06-09 Beiersdorf Ag Verwendung von Licochalkon A gegen Rosacea
DE10356869A1 (de) 2003-12-03 2005-07-07 Beiersdorf Ag Tensidhaltige Zubereitung mit Licochalcon A
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007527418A (ja) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20080044455A1 (en) * 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
RU2335309C1 (ru) * 2007-06-27 2008-10-10 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ комплексного лечения хронического тонзиллита
US9700525B2 (en) * 2008-08-20 2017-07-11 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
CN104367775A (zh) * 2014-12-08 2015-02-25 田丽华 一种用于治疗扁桃体炎的中药
WO2018011790A1 (en) * 2016-07-11 2018-01-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro), (Volcani Center) Treatment of follicular tonsillitis with plant extracts containing carnosic acid
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870210A (en) 1987-12-18 1989-09-26 American Home Products Corporation Aminoguanidine derivative as anti-inflammatory agents
JP3207912B2 (ja) * 1991-03-15 2001-09-10 カネボウ株式会社 コラゲナーゼ活性阻害剤
US5710181A (en) 1991-12-16 1998-01-20 Washington University Inhibition of nitric oxide formation in inflammatory bowel disease
US6048850A (en) 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
GB9602877D0 (en) * 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
GB2317339A (en) * 1996-08-01 1998-03-25 Procter & Gamble Dentifrice composition containing a curcuminoid

Also Published As

Publication number Publication date
ES2258337T3 (es) 2006-08-16
CA2339049A1 (en) 2000-03-16
CA2339049C (en) 2010-02-23
EP1109553B1 (de) 2006-04-26
US6486203B1 (en) 2002-11-26
EP1109553A4 (de) 2003-12-10
WO2000013685A1 (en) 2000-03-16
EP1109553A1 (de) 2001-06-27
DE69931055D1 (de) 2006-06-01
DE69931055T2 (de) 2006-12-07

Similar Documents

Publication Publication Date Title
ATE324105T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
ATE312635T1 (de) Ventilanordnung
DE60128540D1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
ATE202923T1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
DE60138549D1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
ATE371462T1 (de) Verbesserung der herstellung von endogenen gonadotropin
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
EP1363632A4 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
SE9301489D0 (sv) Veterinary composition
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE62414T1 (de) Mittel zur behandlung von herzerkrankungen.
ATE199645T1 (de) Kombination von nekrose-induzierenden substanzen mit substanzen, die durch nekrosen aktiviert werden, zur selektiven therapie von tumoren und entzündlichen erkrankungen
ATE267583T1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
IT1303671B1 (it) Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
DE69324046D1 (de) Protein präparate zur verhütung und behandlung van periodontitis und sonstigen bakteriellen erkrankungen der mundhöhle
PT1343472E (pt) Pulverizacao nasal tixotropica
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
IL138290A0 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
DE69519933D1 (de) Prostaglandinanaloga zur oralen oder vaginalen verabreichung in der routinebehandlung des dritten stadiums der geburtswehen
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
HUP0104652A2 (hu) Nátrium/hidrogén-csere inhibitorok alkalmazása öregkori szervi rendellenességek és öregkori betegségek megakadályozására és az élet meghosszabbítására alkalmas gyógyszerkészítmények előállítására
BR0308795A (pt) Amidas do ácido sulfamico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties